When FDA Plays God, Patients and Doctors Need to Step Up

The patients and doctors expect FDA to approve products based only on credible scientific data, but a few cases have shown that FDA does not always do that. In those cases, it falls on patients and their doctors to make sensible decisions based on facts before embarking on uncertain therapies carrying astronomical price tags.  FDA … Read more

Is FDA in Trouble: NY Times Thinks So 

FDA is approving new drugs and medical devices too fast, its reviewers are leaving for jobs in the industry they regulate, and it is critically short on resources, the editors of the New York Times opined this week. Another article this week in the Journal of American Medical Association (JAMA) by Harvard researchers, raised similar … Read more

Use of Digital Devices in Clinical Trials Increased About 6 Folds in Last 10 Years  

About 1200 currently ongoing clinical trials in the US are using digitally connected tools such as wearable devices and mobile apps. That’s a 6-fold increase from about 200 such trials in 2009. However, with about 22,000 studies ongoing in the US, this is a small fraction of all clinical trials. There are several obvious benefits … Read more

FDA’s Foreign GMP Audits Are Inadequate, Reports GAO 

The GAO reports this week that FDA is severely short of inspectors capable of auditing foreign sites, it gives up to 12 weeks’ notice to foreign sites prior to inspections giving them ample opportunity to clean-up and cover deficiencies, and its inspectors for foreign sites are given inadequate time to complete their job making them … Read more

The Conundrum of CBD Products for Medical Professionals

A perspective in the Journal of American Medical Association (JAMA) presents the unique challenge faced by medical professionals regarding use of CBD products by their patients. CBD products tread a fine line between legal and illegal products. Without any specific disease claims, CBD containing products can be sold as cosmetics or supplements. On the other … Read more

FDA’s Releases an Updated Guidance from Adaptive Trials

Last week FDA released the final guidance document for adaptive trials for drugs and biologics and it contains mostly the same information as the previous guidance documents by the Agency on the topic with some small but critical recommendations. FDA expects the sponsors to include the statistical analysis plan, the Data Monitoring Committee (DMC) charter, … Read more